BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

COPD clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for chronic obstructive pulmonary disease: 198 (122 sponsors; 41 newly posted in the last 180 days, 9 stopped in the last 180 days; 21 new-entrant sponsors). Momentum score 16.9, rank 37 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 20, Phase 2 51, Phase 3 39, Phase 4 7, N/A 80.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Sanofi SNY12NA 3, P3 5, P2 1, P4 2, P1 141
GlaxoSmithKline8P3 5, P1 2, P2 141
AstraZeneca AZN17NA 10, P3 4, P4 2, P2 103
Haisco Pharmaceutical Group Co., Ltd.7P2 4, P3 320
Incyte Corporation INCY7NA 1, P3 3, P2 301
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.4P3 2, P2 202
Grifols Therapeutics LLC GRFS2P3 200
Pfizer PFE2P3 210
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.2P2 1, P3 100
Hoffmann-La Roche2P3 1, P2 110
Joincare Pharmaceutical Group Industry Co., Ltd2P2 1, P3 100
Merck Sharp & Dohme LLC MRK2P2 1, P3 110
Regend Therapeutics2P3 1, EARLY_P1 110
United Therapeutics UTHR new entrant2P3 1, P2 120
Boehringer Ingelheim new entrant1P3 110
Dompé Farmaceutici S.p.A1P3 101
Enanta Pharmaceuticals, Inc ENTA new entrant1P3 110
Eurofarma Laboratorios S.A.1P3 100
Incyte Biosciences Japan GK INCY1P3 100
Janssen Research & Development, LLC1P3 101
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM1P3 100
Fisher and Paykel Healthcare3NA 300
Pulmair Medical, Inc.3NA 300
Reistone Biopharma Company Limited3P1 2, P2 121
Apreo Health, Inc.2NA 200

New-entrant sponsors: United Therapeutics, Boehringer Ingelheim, Enanta Pharmaceuticals, Inc.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT06707883 A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Diseaseactive not recruiting258
2026-12 est.P2Connect Biopharm LLC CNTBNCT07705737 Rademikibart IV for Acute Asthma and COPD ExacerbationAsthma Acute; COPD Exacerbation Acuterecruiting40
2026-12-30 est.P2Meribank Biotech Co., Ltd.NCT06491043 Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem CellsChronic Obstructive Pulmonary Diseaserecruiting90
2027-02 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07464587 Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Diseaserecruiting800

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P2Guangdong Hengrui Pharmaceutical Co., LtdNCT07640451 A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCOPDrecruiting90
2026-09-30 est.P2Joincare Pharmaceutical Group Industry Co., LtdNCT07351734 A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPDCOPD (Chronic Obstructive Pulmonary Disease)recruiting120
2026-09-23P2Uniquity One (UNI)NCT06496620 A Study to Evaluate Solrikitug in Participants With COPD (ZION)COPDactive not recruiting182
2026-09-10P3Sanofi SNYNCT06208306 A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDChronic Obstructive Pulmonary Diseasecompleted669
2026-08-30 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT07108699 Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)active not recruiting180
2026-08-17P2Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT07016412 Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)Chronic Obstructive Pulmonary Diseasecompleted497
2026-07-30P2Connect Biopharm LLC CNTBNCT06940154 Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)COPD Acute Exacerbationcompleted159

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "chronic obstructive pulmonary disease"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.